{"prompt": "['Alliance A171601', '11.4 Guidelines for Evaluation of Measurable Disease', '11.4.1 Measurement Methods', 'All measurements should be recorded in metric notation (i.e., decimal fractions of', 'centimeters) using a ruler or calipers.', 'The same method of assessment and the same technique must be used to characterize each', 'identified and reported lesion at baseline and during follow-up. For patients having only', 'lesions measuring at least 1 cm to less than 2 cm must use CT imaging for both pre- and', 'post-treatment tumor assessments.', 'Imaging-based evaluation is preferred to evaluation by clinical examination when both', 'methods have been used at the same evaluation to assess the antitumor effect of a treatment.', '11.4.2 Acceptable Modalities for Measurable Disease', 'Conventional CT: This guideline has defined measurability of lesions on CT scan', 'based on the assumption that CT slice thickness is 5 mm or less. If CT scans have slice', 'thickness greater than 5 mm, the minimum size for a measurable lesion should be twice', 'the slice thickness.', \"PET-CT: If the site's protocol is to use a PET-CT, then a PET-CT with or without IV\", 'and oral contrast, can be used interchangeably with conventional CT in accurately', 'measuring cancer lesions over time.', 'Physical Examination: For superficial non-nodal lesions, physical examination is', 'acceptable, but imaging is preferable, if both can be done. In the case of skin lesions,', 'documentation by color photography, inc cluding a ruler to estimate the size of the lesion,', 'is recommended.', 'FDG-PET: FDG-PET scanning is allowed to complement CT scanning in assessment', 'of progressive disease [PD] and particularly possible \\'new\\' disease. A \"positive\\' FDG-', 'PET scanned lesion is defined as one which is FDG avid with an update greater than', 'twice that of the surrounding tissue on the attenuation corrected image; otherwise, an', 'FDG-PET scanned lesion is considered \"negative. New lesions on the basis of FDG-', 'PET imaging can be identified according to the following algorithm:', 'Negative FDG-PET at baseline with a positive FDG-PET at follow-up is a sign of', 'PD based on a new lesion.', 'No FDG-PET at baseline and a positive FDG-PET at follow-up:', 'If the positive FDG-PET at follow-up corresponds to a new site of disease', 'confirmed by CT, this is PD.', 'If the positive FDG-PET at follow-up is not confirmed as a new site of disease on', 'CT at the same evaluation, additional follow-up CT scans (i.e., additional follow', '-', 'up scans at least 4 weeks later) are needed to determine if there is truly progression', 'occurring at that site. In this situation, the date of PD will be the date of the initial', 'abnormal PDG-PET scan.', 'If the positive FDG-PET at follow-up corresponds to a pre-existing site of disease', 'on CT that is not progressing on the basis of the anatomic images, it is not classified', 'as PD.', '52', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', '11.4.3 Measurement at Follow-up Evaluation:', 'The cytological confirmation of the neoplastic origin of any effusion that appears or worsens', 'during treatment when the measurable tumor has met criteria for response or stable disease', 'is mandatory to differentiate between response or stable disease (an effusion may be a side', 'effect of the treatment) and progressive disease.', 'Cytologic and histologic techniques can be used to differentiate between PR and CR in rare', 'cases (e.g., residual lesions in tumor types such as germ cell tumors, where known residual', 'benign tumors can remain.)', '11.5 Measurement of Treatment/Intervention Effect', '11.5.1 Target Lesions & Target Lymph Nodes', 'Measurable lesions (as defined in Section 11.3.1) up to a maximum of 5 lesions in total,', 'representative of all involved organs, should be identified as \"Target Lesions\" and recorded', 'and measured at baseline. These lesions can be non-nodal or nodal (as defined in 11.3.1),', 'where no more than 2 lesions are from the same organ and no more than 2 malignant nodal', 'lesions are selected.', 'Note: If fewer than 3 target lesions and target lymph nodes are identified (as there often will', 'be), there is no reason to perform additional studies beyond those specified in the protocol', 'to discover new lesions.', 'Target lesions and target lymph nodes should be selected on the basis of their size, be', 'representative of all involved sites of disease, but in addition should be those that lend', 'themselves to reproducible repeated measurements. It may be the case that, on occasion,', 'the largest lesion (or malignant lymph node) does not lend itself to reproducible', 'measurements in which circumstance the next largest lesion (or malignant lymph node)', 'which can be measured reproducibly should be selected.', 'Baseline Sum of Dimensions (BSD): A sum of the longest diameter for all target lesions', 'plus the sum of the short axis of all the target lymph nodes will be calculated and reported', 'as the baseline sum of dimensions (BSD). The BSD will be used as reference to further', 'characterize any objective tumor response in the measurable dimension of the disease.', 'Post-Baseline Sum of the Dimensions (PBSD): A sum of the longest diameter for all target', 'lesions plus the sum of the short axis of all the target lymph nodes will be calculated and', 'reported as the post-baseline sum of dimensions (PBSD). If the eradiologist is able to provide', 'an actual measure for the target lesion (or target lymph node), that should be rec orded, even', 'if it is below 0.5 cm. If the target lesion (or target lymph node) is believed to be present and', 'is faintly seen but too small to measure, a default value of 0.5 cm should be assigned. If it', 'is the opinion of the radiologist that the target lesion or target lymph node has likely', 'disappeared, the measurement should be recorded as 0 cm.', 'The minimum sum of the dimensions (MSD) is the minimum of the BSD and the PBSD.', '11.5.2 Non-Target Lesions & Non-Target Lymph Nodes', 'Non-measurable sites of disease (Section 11.3.2) are classified as non-target lesions or non-', 'target lymph nodes and should also be recorded at baseline. These lesions and lymph nodes', 'should be followed in accord with 11.5.3.', '53', 'NCIVersion Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}